Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Voss

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Pharmacoepidemiology and Drug Safety|March 23, 2022
Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonistsCristina Rebordosa, Dóra Körmendiné Farkas, Jukka Montonen, et al.
Kidney & Blood Pressure Research|April 9, 2008
Lack of iNOS impairs endothelial function in endothelin-1 transgenic miceThomas Quaschning, Florian Voss, Sophia Herzfeld, et al.
Clinical Colorectal Cancer|October 20, 2019
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 AnalysesHeinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2007
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout miceThomas Quaschning, Florian Voss, Katharina Relle, et al.
Trials|June 30, 2021
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risksRegina Stegherr, Claudia Schmoor, Jan Beyersmann, et al.
British Journal of Haematology|June 9, 2018
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemiaOliver G Ottmann, Carsten Müller-Tidow, Alwin Krämer, et al.
Pediatric Pulmonology|January 30, 2024
Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approachToby M Maher, Kevin K Brown, Steven Cunningham, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Pharmacoepidemiology and Drug Safety|March 23, 2022
Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonistsCristina Rebordosa, Dóra Körmendiné Farkas, Jukka Montonen, et al.
Kidney & Blood Pressure Research|April 9, 2008
Lack of iNOS impairs endothelial function in endothelin-1 transgenic miceThomas Quaschning, Florian Voss, Sophia Herzfeld, et al.
Clinical Colorectal Cancer|October 20, 2019
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 AnalysesHeinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2007
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout miceThomas Quaschning, Florian Voss, Katharina Relle, et al.
Trials|June 30, 2021
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risksRegina Stegherr, Claudia Schmoor, Jan Beyersmann, et al.
British Journal of Haematology|June 9, 2018
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemiaOliver G Ottmann, Carsten Müller-Tidow, Alwin Krämer, et al.
Pediatric Pulmonology|January 30, 2024
Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approachToby M Maher, Kevin K Brown, Steven Cunningham, et al.
Pageof 3